SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

vatiquinone

PTCT·PTC THERAPEUTICS, INC.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
At least 3-4 years away, if ever. PROVE-FA has a 24-month primary endpoint and began enrolling in Q3 2026, so topline data would not be available before late 2028, followed by NDA resubmission and FDA review.
Why 3/10
No hard dated binary catalyst exists in the next ~12 months: the PDUFA decision (August 2025) resulted in a CRL, and the next study (PROVE-FA) is a 24-month open-label trial that began enrolling in Q3 2026 with no announced readout date. Vatiquinone is also not the primary value driver for PTC, which has multiple approved products.
Actionable Insight BEARISH

The next catalyst is the PROVE-FA open-label Phase 3 study (initiated Q3 2026), which will enroll ~120 FA patients aged 7-21 and compare against matched natural history controls over 24 months. A positive readout could support NDA resubmission, but the open-label design may not satisfy the FDA's request for an "adequate and well-controlled study." No topline data is expected before late 2028 at the earliest, so vatiquinone is unlikely to be a near-term stock driver for PTCT.

Price Chart

Loading chart...

Executive Summary

Vatiquinone (EPI-743/PTC-743) is an oral 15-lipoxygenase inhibitor being developed by PTC Therapeutics for Friedreich's ataxia (FA), a rare neurodegenerative disease. The FDA issued a Complete Response Letter in August 2025 declining approval after the pivotal MOVE-FA Phase 2/3 trial missed its primary endpoint (mFARS at 72 weeks). In response, PTC initiated PROVE-FA, a new open-label Phase 3 study in Q3 2026 using matched natural history controls, targeting ~120 patients aged 7-21. With no near-term binary catalyst and the drug already rejected by the FDA, vatiquinone is a minor pipeline component for PTC, which has multiple approved products generating revenue.

How It Works

Vatiquinone is an oral drug that blocks an enzyme called 15-lipoxygenase, which is a key regulator of ferroptosis, a type of inflammatory cell death. By inhibiting this enzyme, vatiquinone aims to reduce brain inflammation and oxidative stress, potentially slowing the progression of Friedreich's ataxia, a rare genetic neurodegenerative disease that causes progressive loss of coordination and muscle function.

Trial Status

The MOVE-FA Phase 2/3 trial (NCT04577352) completed but failed its primary endpoint. A new Phase 3 open-label study called PROVE-FA (NCT07681713) began enrolling in Q3 2026, targeting ~120 FA patients aged 7-21 with a 24-month primary endpoint comparing against matched natural history controls.

The Two-Sided Case

▲ Bull Case4
Long-term open-label data showed a 4.8-point benefit on mFARS versus a matched natural history population (p<0.0001, N=41), suggesting possible disease-modifying activity.
PROVE-FA, initiated in Q3 2026, is designed specifically to address FDA feedback and could support NDA resubmission if positive.
High unmet need exists: no FDA-approved therapy for pediatric Friedreich's ataxia patients, and vatiquinone has Orphan Drug and Fast Track designations.
Analyst consensus on PTCT is bullish (17 Buy/Strong Buy out of 20 ratings) with a mean price target of ~$97.81, implying ~52% upside from the ~$64.46 close.
▼ Bear Case4
The MOVE-FA Phase 2/3 trial failed its primary endpoint (change in mFARS at 72 weeks), and the FDA's August 2025 CRL stated that substantial evidence of efficacy was not demonstrated.
The FDA specifically requested an 'additional adequate and well-controlled study,' but PROVE-FA is an open-label single-arm trial with natural history controls, which may not satisfy that requirement.
Even if PROVE-FA succeeds, NDA resubmission and potential approval are years away (the study has a 24-month primary endpoint), with no near-term binary catalyst.
Vatiquinone is a relatively small part of PTC's overall pipeline; the company has multiple approved products generating revenue, limiting the stock impact of this program.

Upcoming Catalysts

  • PROVE-FA enrollment updates (ongoing, Q3 2026 initiation confirmed)
  • Interim data from PROVE-FA (no date announced)
  • Potential NDA resubmission (contingent on positive PROVE-FA results, likely 2028+ if at all)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report

Sources · 14

Hover a chip for the title
1 ir.ptcbio.com2 en.wikipedia.org3 curefa.org4 ir.ptcbio.com5 curefa.org6 stockanalysis.com7 securities.io8 curefa.org9 ajmc.com10 friedreichsataxianews.com11 download.open.fda.gov12 pharmaphorum.com13 clinicaltrials.gov14 ir.ptcbio.com